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Abstract We previously showed that the cannabinoid receptor
CB1 stably transfected in Chinese hamster ovary cells was
constitutively active and could be inhibited by the inverse agonist
SR 141716A. In the present study, we demonstrate that the
cannabinoid agonist CP-55940 induced cytosol alkalinization of
CHO-CB1 cells in a dose- and time-dependent manner via
activation of the Na+/H+ exchanger NHE-1 isoform. By
contrast, the inverse agonist SR 141716A induced acidification
of the cell cytosol, suggesting that the Na+/H+ exchanger NHE-
1 was constitutively activated by the CB1 receptor. CB1-
mediated NHE1 activation was prevented by both pertussis
toxin treatment and the specific MAP kinase inhibitor PD98059.
NHE-1 and p42/p44 MAPK had a similar time course of
activation in response to the addition of CP-55940 to CHO-CB1
cells. These results suggest that CB1 stimulates NHE-1 by Gi=o-
mediated activation of p42/p44 MAP kinase and highlight a
cellular physiological process targeted by CB1.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Despite the broad physiological e¡ects described for v9-tet-
rahydrocannabinol (v9-THC), the main active substance of
marijuana, its mechanism of action only began being de-
scribed a few years ago following the identi¢cation and clon-
ing of the speci¢c cannabinoid receptor. The central cannabi-
noid receptor (CB1) was cloned from both rats and humans
[1,2] and shown to be expressed primarily in brain tissues
[3,4]. CB1 mRNA has also been found to a lesser extent in
testis [3], spleen [5] and leukocytes [6]. A second cannabinoid
receptor (CB2) was cloned and recently characterized. CB2 is
expressed in macrophages from the marginal zone of spleen,
in B lymphocytes and NK cells, but not in brain tissues [7,8].
Both CB1 and CB2 receptors belong to the G-protein-coupled
receptor (GPCR) superfamily.
It is now clearly established that v9-THC and other potent
synthetic cannabinoid receptor agonists, as well as anand-
amide and 2-arachidonylglycerol, the putative endogenous li-
gands [9^11], bind speci¢cally to cannabinoid receptors.
CB1 and CB2 stimulation induces several biological re-
sponses, including inhibition of adenylyl cyclase (AC) [12^
14], activation of mitogen-activated protein kinases (MAPK)
[15,16], induction of the immediate-early gene (IEG) Krox 24
in vitro [16,17] and also in vivo [18,19]. CB1, but not CB2,
was shown to induce ion channel modulation [20,21]. These
cannabinoid e¡ects are mediated by a pertussis toxin (PTX)-
sensitive guanine nucleotide-binding protein (Gi protein). The
CB1 coupled cellular responses were selectively prevented by
the speci¢c potent CB1 antagonist SR 141716A [22,23].
We recently showed that SR 141716A displayed a negative
intrinsic activity towards the autoactivated CB1 transfected in
Chinese hamster ovary (CHO) cells and that this inverse ago-
nist was able to negatively control signal transduction medi-
ated by Gi-dependent receptor tyrosine kinases like insulin or
IGF1 [24].
Na/H exchangers (NHE) are key electroneutral trans-
membrane transporters involved in multiple cellular functions,
such as intracellular pH regulation, control of cell volume and
transepithelial ion transport. To date ¢ve distinct isoforms of
NHE, which di¡er in their kinetics and pharmacological prop-
erties, have been identi¢ed in mammalian cells (review in [25]).
They are di¡erentially expressed in various tissues, suggesting
that the individual isoforms have distinct functions.
NHE-1, the ¢rst Na/H exchanger isoform to be cloned
[26], is ubiquitously expressed and appears to be the predom-
inant species in non-epithelial cells where it has been shown to
play a major role in pHi homeostasis and cell volume regu-
lation [27]. NHE-2 and NHE-3 are prominent in intestinal
and renal tissues where they take part in transepithelial
NaCl transport. The two other isoforms NHE-4 and NHE-5
have not been fully characterized.
NHE-1 activity can be modulated by a remarkably wide
variety of stimuli, including growth factors, cytokines, tumor
promoters, hormones and physical factors such as changes in
cell volumes, or cell spreading [27]. Extracellular stimuli were
shown to activate NHE-1 by increasing its sensitivity to intra-
cellular H, resulting in cytoplasmic alkalinization [28^30].
The mechanism underlying this shift in pHi sensitivity has
not yet been fully elucidated. The p42/p44 MAPK cascade
was recently shown to play a major role in the activation of
NHE-1 by growth factors [31] or hormones such as arginine
vasopressin [32].
The experiments described in this article were conducted to
explore the cannabinoid receptor CB1 induction e¡ect on
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Na/H exchanger activity in CHO cells transfected with
CB1.
2. Materials and methods
2.1. Reagents
[Q-32P]ATP (3000 Ci/mmol) was from Amersham (Les Ulis, France).
PTX was purchased from Sigma Chemicals (Saint-Quentin-Fallavier,
France). Insulin was purchased from Preprotech (TEBU). SR
141716A (N-(piperidino-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophen-
yl)-4-methyl-pyrazole-3-carboxamide) and CP-55940 were synthesized
in the Chemistry Department of Sano¢ (Montpellier, France). G418
was from Gibco BRL (Cergy Pontoise, France). [7-14C]benzoic acid
was purchased from DuPont NEN. HOE694 was kindly provided by
Hoechst Laboratories. The speci¢c MEK1 inhibitor PD98059 was
from Biolabs.
2.2. Expression of human CB1 receptor in CHO cells
CB1 cDNA from IM-9 [33] was ampli¢ed with a sense primer
bearing a HindIII site and a Kozak consensus sequence (5P-CCACA-
CAAGCTTGCCACCAT-GGAGGAATGCTGGGTG) and an anti-
sense primer bearing an EcoRI site (5P-CCACTCGGATCCTCAG-
CAATCAGAGAGGTCTAG). The amplicon was digested with Hin-
dIII/EcoRI and inserted into p658, an expression plasmid derived
from p7055 [34] in which the interleukin-2 coding sequence was re-
placed by a polylinker. The CB1 expression vector was transfected
into CHO dihydrofolate reductase-negative cells by a modi¢ed CaPO4
precipitation method [35]. CHO cells transfected with CB1 cDNA and
expressing CB1 are referred to as CHO-CB1 cells. The CHO-CB1 cells
were grown as monolayers in minimal essential medium supplemented
with 5% dialyzed fetal calf serum, 2 mM glutamine, 40 Wg/ml L-pro-
line, 60 Wg/ml Tylocine, 1 mM sodium pyruvate and 5 Wg/ml genta-
micin.
2.3. MAPK assay
MAPK activity was measured as described previously [15]. Brie£y,
cells grown to 80% con£uence in 24-well plates were placed in medium
containing 0.5% FCS (0% FCS when v9-THC was used) for 24 h
before assay. After treatment, cells were washed twice in bu¡er A
(50 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM Na4P2O7, 50 mM
NaF, 1 mM EDTA, 20 mM glycerophosphate, 1 mM EGTA, 2 mM
Na4VO4) and lysed for 15 min in 100 Wl of bu¡er A containing 1% (v/
v) Triton X-100, 100 U/ml aprotinin, 20 WM leupeptin, 0.2 mg/ml
PMSF and 2 mM dithiothreitol. Solubilized cell extracts were centri-
fuged at 14 000Ug for 15 min and 18 Wl of supernatants (20 Wg
proteins) were analyzed for MAPK activity. The protein contents in
the supernatants were determined using the micro BCA protein assay
kit (Pierce). Phosphorylation of MAPK-speci¢c peptide substrate
was carried out at 30‡C for 30 min (linear assay conditions) with
[Q-32P]ATP using the Biotrack p42/p44 MAP kinase enzyme system
(Amersham).
2.4. Measurement of intracellular pH changes
Intracellular pH changes were estimated from the distribution of
[7-14C]benzoic acid, as described previously [36]. CHO-CB1 cells were
grown to con£uence in 24-well plates and incubated for 5 h in the
serum-free medium to maintain the Na/H exchanger in a resting
state. Cells were further incubated for 1 h at 37‡C in a serum- and
HCO33 -free medium containing 120 mM NaCl, 1 mM MgCl2, 2 mM
CaCl2, 5 mM KCl, 5 mM glucose and 20 mM HEPES at pH 7.0.
Cells were then placed for 15 min in the same medium containing
7 Bq/ml [14C]benzoic acid (0.3 WCi/ml) in the presence or not of
CP-55940, as described in the ¢gure legends. Cells were then rapidly
washed four times with ice-cold PBS and 14C radioactivity was
counted.
2.5. Transient expression and H+-killing selection
H-killing selection was used for transient expression. CHO-CB1
cells were grown for 2 days (4U105 cells/well) in 6-well plates and
transfected with 1 Wg/well of mock or NHE-3 expression vector [37]
by the lipofectamine technique [38]. Forty-eight hours after transfec-
tion, cells were subjected to acid-load selection [39] in the presence of
1 WM HOE694, (a selective NHE-1 blocker) to inhibit endogenous
NHE1 antiporter activity, so that only transfected cells expressing
the NHE3 isoform survived [40]. The surviving cells were counted 3
days later by trypan blue staining.
3. Results
3.1. E¡ect of CP-55940 on cytosolic pH
The e¡ect of CP-55940 on cytosolic pH was studied in
CHO cells stably transfected with CB1 (CHO-CB1) [15].
Changes in pHi were estimated from the distribution of
[14C]benzoic acid as described in Section 2. CP-55940 treat-
ment of CHO-CB1 cells induced a rapid and persistent cyto-
plasmic alkalinization, which peaked (vpHi = 0.2 þ 0.02) at
10 min (Fig. 1A). The CP-55940-induced pHi rise was dose-
dependent, with an EC50 of 9 nM, which is consistent with the
binding a⁄nity of CP-55940 (Fig. 1B).
3.2. Identi¢cation of the NHE isoform a¡ected following
CP-55940 treatment
The process responsible for CP-55940-induced alkaliniza-
tion was then investigated. As the experiments in Fig. 1
were performed in the absence of HCO33 , the observed pHi
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Fig. 1. E¡ect of CP-55940 on cytosolic pH. CHO-CB1 cells were
depleted of serum for 5 h and then equilibrated for 1 h in bicarbon-
ate-free and HEPES-bu¡ered saline (pH 7) as described previously
[31]. Then the cells were incubated for 15 min in the same medium
containing 0.3 WCi/ml [14C]benzoic acid in the absence or presence
of CP-55940. Variations in pHi were measured as described in [36].
vpHi represents the pHi variation relative to the control (unstimu-
lated cells). Error bars ( þ S.E.M.) are based on quadruplet determi-
nations. A: Kinetics of CP-55940 (20 nM)-induced pHi increases.
B: 15 min treatment with increasing CP-55940 concentrations.
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changes could probably not be explained by the involvement
of HCO33 /Cl
3 exchange. We therefore turned our attention to
the Na/H exchanger. NHE-1 is ubiquitously expressed and
appears to be the predominant species in non-epithelial cells
[25]. We thus tested whether the inhibition of NHE-1 by the
NHE-1 selective inhibitor HOE694 (Ki (WM) NHE-1, 0.16;
NHE-2, 5; NHE-3, 650) [40] could a¡ect CP-55940-induced
cytosol alkalinization. In Fig. 2A, we clearly show that
HOE694 dose-dependently inhibited the CP-55940-induced
pHi rise, suggesting that NHE-1 is the predominant isoform
mediating CP-55940-induced cytosol alkalinization. Interest-
ingly, we observed that HOE694 also a¡ected the basal pHi
(30% pHi reduction in comparison to non-HOE694-treated
cells), suggesting that the NHE-1 in CHO-CB1 cells had a
certain degree of constitutive activity.
To con¢rm that CP-55940-induced cytosol alkalinization
was due to NHE-1 activation, we performed acid-load selec-
tion of mock or NHE-3 transiently transfected CHO-CB1
cells in the presence or absence of HOE694. The results in
Fig. 2B clearly show that the mock transfected cells survived
(100%) in the absence of HOE694, whereas NHE-1 blockage
by HOE694 induced 95% cell death. By contrast, NHE-3-ex-
pressing cells resisted acid-load selection even in the presence
of HOE694. These results con¢rmed that NHE-1 is the sole
Na/H exchanger isoform functionally active in CHO-CB1.
3.3. E¡ect of SR 141716A on cytosolic pH
To test the speci¢city of the central cannabinoid receptor
involvement in CP-55940-induced cytosol alkalinization, we
treated the CHO-CB1 cells with the CB1 selective inverse
agonist SR 141716A. The results reported in Fig. 3 clearly
show that SR 141716A (100 nM) not only antagonized the
ability of CP-55940 (10 nM) to induce intracellular alkaliniza-
tion but also a¡ected the basal activity of NHE-1, suggesting
that the constitutive NHE-1 activation observed previous-
ly was induced by the autoactivated CB1 receptor. Further-
more, we noted that insulin stimulated the pHi rise
(vpHi = 0.3 þ 0.04) and that SR 141716A also attenuated the
insulin-induced NHE-1 activation (Fig. 3). These results are in
accordance with those of our previous study, where SR
141716A negatively modulated Gi-dependent receptor tyro-
sine kinase (RTK) signaling or GPCR signaling in CHO-
CB1 cells [24].
3.4. Mechanism of CP-55940-induced NHE-1 activation
To further investigate the e¡ector pathway responsible for
NHE-1 activation in CHO-CB1 cells, we ¢rst examined the
e¡ect of PTX on the NHE1 stimulation potential of CP-
55940. As shown in Fig. 4, the stimulation of NHE-1 activity
by CP-55940 was inhibited following PTX treatment (100 ng/
ml), which was consistent with the selective coupling of CB1
to Gi/Go proteins. We also observed that PTX treatment re-
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Fig. 3. E¡ect of SR 141716A on the cytosolic pH. Quiescent CHO-
CB1 cells were pretreated with SR 141716A (100 nM) for 10 min
before activation by CP-55940 (10 nM) or insulin (1 Wg/ml) for
15 min. The pHi was measured as described in the legend to Fig. 1.
Data are means of quadruple determinations and are representative
of experiments repeated three times.
Fig. 2. CP-55940-activated pHi increase was NHE-1 mediated. A:
HOE694-induced inhibition of CP-55940-activated pHi increase:
CHO-CB1 cells were pretreated for 10 min with increasing concen-
trations of HOE694 (0.001^1 WM) before activation with CP-55940
(20 nM) for another 15 min. The pHi modulation was determined
as described in the legend to Fig. 1. B: CHO-CB1 cell death by H
suicide in the presence of HOE694 was prevented by NHE-3 trans-
fection: CHO-CB1 cells were transiently transfected by the NHE-3
or mock expression vector as described in Section 2. Two days after
transfection, cells were subjected to H suicide methods in the pres-
ence or absence of HOE694 (1 WM), as described in Section 2, and
cell viability was determined as % of cell growth 3 days later. The
viability of NHE-3+HOE694 was underestimated since transfection
e⁄cacy was approximately 30^40%.
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duced the basal activity of NHE-1, which is in agreement with
results obtained with SR 141716A and consistent with the
features of autoactivated receptors.
MAPK signaling is among the signaling events located
downstream from the G protein and leading to NHE-1 acti-
vation. MAPK activation was previously shown to be linked
to NHE-1 activation [31,32]. To test whether CP-55940-acti-
vated p42/p44 MAPK could regulate NHE-1 activation in
CHO-CB1 cells, we used a MEK1 inhibitor PD98059 [41].
As shown in Fig. 4, PD98059 at 10 WM inhibited 80% of
the activation of MAPK by CP-55940. PD98059 was also
found to signi¢cantly inhibit the response of NHE-1 to both
CP-55940 (50%) and insulin (45%) (not shown), highlighting
the role of p42/p44 MAPK induction in CP-55940 activation
of NHE-1.
4. Discussion
In this study, we clearly demonstrate that CP-55940 in-
duced NHE-1 activation in a dose- and time-dependent man-
ner in CHO-CB1 cells and that this induction was speci¢cally
CB1-mediated. Consequently, NHE-1 activation leads to cy-
tosol alkalinization. We also showed that treatment of CHO-
CB1 cells with the speci¢c NHE-1 inhibitor HOE694, with the
CB1 selective inverse agonist SR 141716A, or with PTX low-
ered the basal pHi by more than vpHi = 0.12 þ 0.03. Overall,
these results indicated that autoactivated CB1 constitutively
a¡ected the basal activity of NHE-1 in CHO-CB1 cells. Fur-
thermore, the magnitude of the CP-55940-induced pHi rise
(vpHi = 0.2) was underestimated (since we obtained vpHi val-
ues of 0.3 when cumulating SR 141716A and CP-55940 ef-
fects). This is the ¢rst demonstration that a NHE1 exchanger
can be constitutively a¡ected by the autoactivated GPCR.
We also observed that SR 141716A could negatively mod-
ulate insulin-induced NHE-1 activation. Insulin induced
NHE-1 activation via a PTX-dependent G-protein (not
shown); this is consistent with our previous report, which
showed that the inverse agonist SR 141716A could interfere
with Gi-dependent signaling mediated by both GPCR and
RTK [24].
Our observations could be extended to the CB2 receptor,
since we also observed that the peripheral cannabinoid recep-
tor CB2 stably transfected in CHO cells induced NHE-1 acti-
vation (vpHi = 0.26 þ 0.018) in a PTX-sensitive manner (not
shown).
GPCR modulation of NHE-1 activity is well documented.
Most GPCRs stimulate NHE1 activity through coupling to
Gq, G13 or Gi=o GTP binding proteins [42]. On the other
hand, dopamine receptors [43], somatostatin receptors [44]
or constitutively active GK12 inhibit NHE-1 activity [45].
In CHO-CB1 cells, PTX prevented CP-55940-induced
MAPK and NHE-1 activation, indicating Gi=o protein in-
volvement.
The MEK1-speci¢c inhibitor PD98059 (at 10 WM) pre-
vented CP-55940-induced MAPK activation by up to 80%,
but inhibited CP-55940-induced NHE-1 activation by only
50%. The residual MAPK activity could be su⁄cient to pro-
duce NHE-1 activation. Alternatively these results could also
suggest that, in addition to the Gi=o p42/p44 MAPK signaling
cascade, CB1 induced NHE-1 activation via another Gi=o-de-
pendent but p42/p44 MAPK-independent signaling pathway.
Gi=o-dependent but p42/p44 MAPK-independent signaling ac-
tivation of NHE1 has been implicated in NHE-1 activation by
5-HT1A receptors transfected in CHO cells [46]. CB1 might
use another signaling cascade such as cdc42-MEKK1, which
has been shown to be involved in NHE-1 activation [47].
There is also possible involvement of NHERF (Na/H ex-
changer regulatory factor) PDZ proteins which were shown to
be involved in the regulation of L2 adrenoreceptor-induced
NHE-3 activation by direct interaction with the DSLL (D
S/T X L consensus) motif in the C-terminal tail of L2 adre-
noreceptors [48,49]. Analysis of the CB1 C-terminal tail
showed a DTSV motif, which is a potential binding site of
PDZ proteins.
As the above results were obtained with CHO cells over-
expressing CB1, we next examined whether they could be ex-
tended to human cell lines expressing endogenous CB1. We
thus used the U373MG astrocytoma cell line which expresses
CB1 [15,16]. We previously observed that CB1 stimulation
induced MAPK activation and Krox24 expression. In
U373MG cells, we observed a slight increase in pHi
(vpHi = 0.095 þ 0.02) after CP-55940 treatment (data not
shown).
The central nervous system is a well-known target of sys-
temic acid-base disorders. There is growing evidence that rap-
id and local pH transients may alter neuronal excitability. A
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Fig. 4. E¡ect of PTX and PD98059 on CP-55940-induced MAPK
and NHE-1 activation. Growth-arrested CHO-CB1 cells were pre-
treated with PTX (100 ng/ml) for 5 h or with PD98059 (10 WM) for
1 h and then activated with CP-55940 (20 nM). A: After 10 min
the cells were lysed and MAPK activity was determined as described
in Section 2. B: pHi was determined 15 min later, as described in
the legend to Fig. 1.
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wide variety of neuronal signaling mechanisms are pH-de-
pendent, including membrane voltage- and ligand-gated ion
channels, transmitter uptake through transporters, intracellu-
lar signal transduction, and intracellular communication via
gap junctions [50]. Although we did not analyze the e¡ect of
cannabinoid ligands on NHE-1 activity in neuronal cells, we
hypothesize that cannabinoid ligands may regulate neuronal
excitability by modulating NHE-1 activity. This hypothesis
could be related to the observation that the CB1 agonist v9-
THC and endocannabinoids, such as anandamide, lowered
neuronal excitability by inhibiting neurotransmitters (gluta-
mate, dopamine) release [51].
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